Skip to content 
EBOO therapy for chronic inflammation is one of the most requested topics from patients at our clinic. Chronic inflammation is not a single disease. It is an underlying process that drives fatigue, joint stiffness, brain fog, and dozens of other symptoms that conventional medicine often struggles to resolve.
Research on ozone therapy and inflammation is the strongest evidence in the entire EBOO conversation. Published studies show that medical ozone activates the NRF2 antioxidant pathway, suppresses NF-kB inflammatory signaling, and reduces measurable markers like TNF-a, IL-6, and CRP.
But there is a critical distinction. Most of those research studies are on ozone therapy generally, not EBOO specifically. This guide explains what the science actually supports, what EBOO therapy for chronic inflammation looks like in practice, and how to decide whether it makes sense for you.
If you are new to EBOO, start with what EBOO therapy is. This article focuses specifically on the inflammation question.
Acute inflammation is your body’s normal healing response. You cut your finger, the area swells, immune cells rush in, repair happens. That is healthy inflammation doing its job. Chronic inflammation is different. It is a persistent, low-grade immune response that does not shut off. Instead of protecting you, it quietly damages healthy tissue over months and years.
The signs are often vague. Persistent fatigue that sleep does not fix. Morning joint stiffness. Brain fog. Digestive problems. Skin issues. Slow recovery from illness. General discomfort without a clear diagnosis.
What makes it frustrating is that conventional blood work may not always flag it clearly. CRP and ESR can be mildly elevated without pointing to a specific cause. Patients end up in a gray zone where they feel terrible, but their labs look mostly normal.
This is the gap where many patients begin exploring EBOO therapy for chronic inflammation as a complementary approach alongside conventional care.
The proposed anti-inflammatory effect of EBOO therapy for chronic inflammation works through three pathways. The strength of the science behind each varies.
When ozone contacts blood, it creates a brief, controlled oxidative stress. This produces lipid ozonation products (LOPs) that act as signaling molecules throughout the body.
These molecules activate the NRF2 pathway. NRF2 is your body’s master antioxidant switch. Once activated, it upregulates three critical internal defenses: superoxide dismutase (SOD), catalase, and glutathione.
At the same time, the NF-kB pathway gets suppressed. NF-kB is the master inflammatory switch. When it is overactive, your body produces excess pro-inflammatory cytokines. Suppressing it reduces TNF-α, IL-1β, and IL-6 production.
A 2017 study on multiple sclerosis patients found that ozone therapy significantly reduced TNF-α and IL-1β while activating NRF2 phosphorylation. A 2021 comprehensive review confirmed this dual mechanism across multiple chronic inflammatory conditions, including rheumatoid arthritis.
This NRF2/NF-kB pathway is the strongest evidence in the entire ozone therapy conversation. It is well-documented, reproducible, and published in peer-reviewed journals.
The complete research breakdown is in EBOO therapy research and clinical evidence.
This is where EBOO differs from every other form of ozone therapy. The EBOO system passes blood through a dialysis-like filter that captures larger molecular debris.
In chronic inflammation, oxidized proteins, immune complexes, lipid peroxides, and cellular waste circulate continuously. These byproducts fuel the inflammatory cycle. During the session, the filter physically removes debris above its molecular-weight cutoff.
No controlled trial has shown whether this produces a clinically meaningful reduction in inflammatory load. But the mechanism is straightforward. Practitioners consistently report that patients with high inflammatory burden show the most visible debris in the filter.
For details on what the filter does and does not capture, read what EBOO filters actually capture from your blood.
Chronic inflammation impairs tissue oxygenation. Impaired oxygenation perpetuates inflammation. This creates a self-reinforcing cycle.
The oxygenation component of EBOO is proposed to help interrupt this cycle by improving oxygen delivery to damaged tissues. The Di Paolo 2005 trial measured improved tissue healing in peripheral artery disease patients, a condition driven by inflammatory vascular damage.
The evidence falls into three tiers, and being honest about the distinction matters.
Multiple studies report NRF2 activation, NF-kB suppression, and cytokine reduction. The 2021 Viebahn-Haensler review, the 2017 multiple sclerosis study, and the 2020 psoriasis trial all confirm this pathway. This is solid, reproducible science.
The only EBOO-specific clinical evidence comes from Di Paolo et al., a 2005 controlled trial with 28 patients and a 2000 case series with 82 patients. Both showed positive results, but both studied peripheral artery disease, not general chronic inflammation. Both came from the same research group.
Practitioners consistently report filtering visible inflammatory debris during EBOO sessions. Patients with high inflammatory burden tend to show the most dramatic filter changes. But visible debris in a filter does not prove clinical benefit. This needs a controlled study.
No large controlled trial has confirmed whether EBOO therapy for chronic inflammation produces these effects to a clinically meaningful degree. This is an honest limitation that responsible clinics acknowledge.
The evidence tiers are explained in detail in EBOO therapy benefits: what is proven, proposed, and just marketing.
EBOO therapy for chronic inflammation usually makes the most sense for patients who have already tried standard approaches. That means dietary changes, stress management, sleep optimization, and any medications prescribed by their doctor. If those approaches haven’t resolved persistent symptoms and lab work shows ongoing elevated inflammatory markers, EBOO may be worth discussing with a qualified provider.
Patients who report the most noticeable response typically have measurable inflammation (elevated CRP, ESR, or specific cytokines), persistent symptoms for more than six months despite conventional treatment, and no undiagnosed underlying condition that needs to be addressed first.
At Purefico Medspa and Longevity Center in Cornelius, NC, we require a consultation before starting EBOO. We review your symptoms, medical history, and existing lab work to determine whether EBOO could add value alongside your current care.
EBOO will not cure the underlying cause of your inflammation. If you have an undiagnosed autoimmune condition, a chronic infection, or an environmental trigger, EBOO may temporarily reduce symptoms. But the inflammation will return until you address the root cause.
EBOO will not replace medications your doctor prescribed. If you are on biologics, corticosteroids, or other anti-inflammatory treatments, EBOO is an adjunct, not a substitute.
EBOO will not produce overnight results. Chronic inflammation developed over months or years. Meaningful improvement typically requires multiple sessions over several weeks.
For contraindication details, read EBOO therapy contraindications: who should not have it.
EBOO does not work in isolation. What you do between sessions directly affects your results.
Full nutrition guidance is in what to eat and drink before and after EBOO therapy.
Inflammation is the most common concern I see in patients who come to Purefico for EBOO. Many of them have spent years trying to find relief and have been told their labs look normal despite feeling terrible.
What I can offer is an honest assessment. For some patients, EBOO makes a meaningful difference. For others, we need to address the underlying cause first. My job is to figure out which situation you are in, not to sell you sessions.
EBOO therapy for chronic inflammation is an area of active clinical interest. The proposed mechanism, NRF2 activation and NF-kB suppression, is well-documented for ozone therapy in general. No large trial has confirmed whether EBOO produces clinically meaningful effects. Practitioners and patients report improvements, but controlled evidence specific to EBOO is limited.
Based on the broader ozone research, markers most commonly studied include C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), TNF-α, IL-6, and IL-1β. Whether EBOO specifically moves these markers depends on the patient’s condition and baseline levels.
Most practitioners recommend at least three sessions to assess response, typically one to two weeks apart. Some patients notice improvement after one or two sessions. Others need a longer course. Your provider should evaluate at the three-session mark.
EBOO processes more blood and includes filtration that standard IV ozone lacks. No controlled study has compared whether this makes it more effective for inflammation. Starting with less intensive IV ozone to test your response is often a reasonable and more affordable first step.
The comparison is explained in IV ozone therapy vs EBOO: which do you actually need.
No. EBOO is classified as experimental and elective. Insurance does not cover it for any condition. A typical course of three to six sessions costs between $750 and $4,800 out of pocket.
In most cases, yes. EBOO therapy for chronic inflammation can be used alongside prescribed anti-inflammatory medications, but your provider must review your full medication list first. Some medications, particularly anticoagulants, require careful coordination.
Yes. Purefico Medspa and Longevity Center in Cornelius, near Charlotte, offers EBOO therapy for patients dealing with chronic inflammation. We require a consultation and proper screening before beginning sessions.
1. Viebahn-Haensler R, Leon Fernandez OS. Ozone in medicine: the low-dose ozone concept and its basic biochemical mechanisms of action in chronic inflammatory diseases. International Journal of Molecular Sciences. 2021;22(15):7890.
2. Re L, et al. Medical ozone promotes NRF2 phosphorylation, reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. European Journal of Pharmacology. 2017;811:148-154.
3. Zeng J, et al. Ozone therapy attenuates NF-kB-mediated local inflammatory response and activation of Th17 cells in psoriasis treatment. International Journal of Biological Sciences. 2020;16(12):2116-2130.
4. Di Paolo N, Bocci V, Salvo DP, et al. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. International Journal of Artificial Organs. 2005;28(10):1039-1050.
5. Bocci V, Zanardi I, Travagli V. Ozone acting on human blood yields a hormetic dose-response relationship. Journal of Translational Medicine. 2011;9:66.
6. Cacciatore S, et al. Effectiveness and safety of ozone therapy: an umbrella review. Medical Sciences (Medicina). 2026;14(2):289.
7. U.S. Food and Drug Administration. 21 CFR 801.415, Maximum acceptable level of ozone.
Melissa Lynch, NP, is a nurse practitioner with 28 years of clinical experience and the founder of Purefico MedSpa & Therapy, with locations in Cornelius and Archdale, North Carolina.
